Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-04833-3
Abstract: SummaryTreatment with zoledronic acid 5 mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50 mg weekly.IntroductionThe development of… read more here.
Keywords: treatment; treatment zoledronic; bone loss; zoledronic acid ... See more keywords